Compare FEIM & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | DSGN |
|---|---|---|
| Founded | 1961 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 853.8M |
| IPO Year | 1994 | 2021 |
| Metric | FEIM | DSGN |
|---|---|---|
| Price | $74.43 | $13.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $51.50 | $15.25 |
| AVG Volume (30 Days) | 410.1K | ★ 490.1K |
| Earning Date | 03-11-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $63,227,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.55 | $4.23 |
| 52 Week High | $80.52 | $17.25 |
| Indicator | FEIM | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.83 | 59.73 |
| Support Level | $44.48 | $9.78 |
| Resistance Level | $76.84 | $17.10 |
| Average True Range (ATR) | 6.28 | 0.73 |
| MACD | 0.73 | 0.15 |
| Stochastic Oscillator | 75.17 | 86.70 |
Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.